Liver fat / MASH peptides
Compounds studied for hepatic fat and metabolic-liver outcomes, mostly within metabolic-drug programs.
S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.
The category at a glance
Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.
Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.
SsemaglutideStrong human evidenceLow overstatementFDA-approved95/ 100
A GLP-1 receptor agonist with large randomized human trials behind it. The STEP program studied it for chronic weight management and SUSTAIN for type-2 diabetes; it is FDA-approved (Wegovy, Ozempic). The strongest weight/glucose evidence of any compound in this space — with well-documented GI side effects and the need for ongoing use.
Tier read: strong human evidence · low overstatement risk · low search interest · Approved use. Why not A: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
Read the full semaglutide profile →AtesamorelinStrong human evidenceLow overstatementFDA-approved87/ 100
The most clinically validated compound in this group. A pivotal 412-patient randomized, placebo-controlled trial (Falutz, NEJM 2007) showed ~15% reduction in visceral fat in HIV-associated lipodystrophy, and it is FDA-approved as EGRIFTA for that indication. Caveats: benefits aren't sustained after stopping, and approval is narrow — not general anti-aging or body-composition use.
Tier read: strong human evidence · low overstatement risk · low search interest · Approved use. Why not B: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance. Why not S: held back by remaining gaps and limited replication.
Read the full tesamorelin profile →BretatrutideStrong human evidenceLow overstatementInvestigational68/ 100
An investigational triple agonist (GIP/GLP-1/glucagon). A phase-2 randomized trial reported large weight reductions, but it is not approved and lacks the long-term phase-3 safety record of semaglutide and tirzepatide. Promising early human data, still investigational.
Tier read: strong human evidence · low overstatement risk · low search interest · Clinical trials. Why not C: supported by human evidence, preclinical depth, mechanism confidence, practical relevance. Why not A: held back by regulatory clarity.
Read the full retatrutide profile →Liver-fat and metabolic-liver outcomes sit mostly inside the larger metabolic-drug programs. The compounds with the most relevant evidence are the same incretin and GHRH drugs studied for metabolic disease — not standalone “liver peptides.”
Start with the best-supported options first: semaglutide, tesamorelin. Then compare them before exploring research-only compounds.
- This liver fat / mash overview (you're here)
- semaglutide
- tesamorelin
- semaglutide vs tesamorelin
- Safety & quality guide
What the evidence actually supports
Investigational and approved metabolic agents (retatrutide, semaglutide, tesamorelin) have been studied for hepatic fat as part of broader metabolic programs. Tesamorelin is approved for a visceral-fat indication; the others are studied for liver-fat outcomes in trials.
Where the hype outruns the data
Self-directed treatment of liver disease and “reversing liver damage” without medical care are not supported uses. Liver disease is a medical condition that needs clinical evaluation, not a research peptide.
FAQ
Can peptides treat fatty liver?
Some metabolic drugs are studied for hepatic fat in trials, but self-directed treatment of liver disease isn't a supported use — it needs medical care.
Is this medical advice?
No — research reference only.
Which compounds are relevant here?
Largely the metabolic agents (retatrutide, semaglutide, tesamorelin) studied within liver-fat research programs.
Research reference only. Not medical advice, dosing, or a recommendation to use any compound. “Worth watching” ≠ proven or safe.